GenSight CEO Sees Bright Future After Therapy Gave Blind Man Partial Sight
GS030’s Development Will Now Get Higher Priority
French biotech GenSight will prioritize its optogenetic GS030 treatment after the combination showed breakthrough results in a form of blindness, its CEO tells Scrip.
You may also be interested in...
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.
Mikaela Odlander, one of In Vivo’s 2021 Rising Leaders, was appointed director of digital therapeutics at Orexo in November 2019. The newly formed digital therapeutics (DTx) arm of the Swedish pharma and digital health company entered the American health care landscape in 2020 with two new products that address substance abuse and mental health problems.
Biogen’s investigational anti-tau antibody gosuranemab has missed its primary efficacy endpoint in a Phase II study in patients with Alzheimer's disease, prompting the end of the trial and termination of the compound’s further clinical development.